|
市場調查報告書
不使用抗體的癌疫苗競爭動向
Competitive Outlook on Non-Antibody Based Cancer Vaccines
|
不使用抗體的癌疫苗競爭動向 是由出版商BioSeeker Group AB在2006年08月所出版的。
這份英文市場調查報告書包含138 pages 價格從美金2828起跳。
DNA疫苗及新合併疫苗等新興研究持續地進行。癌疫苗產業在過去3年內也有大規模的改革活動。然而現今的癌疫苗相關企業數卻有不增反減的現象。
近年來在製藥與生物科技領域急速竄起的瑞典市調公司 BioSeeker Group ，調查與分析不使用抗體的癌疫苗競爭動向，並有系統地出版綜合報告書 "Competitive Outlook on Non-Antibody Based Cancer Vaccines" 。
此報告書在下面的內容裡，除了說明癌疫苗市場的競爭動向與腫瘤抗原開發技術、免疫調整策略清單，也探討6項主要癌疫苗的發展分析、相關企業動向等。
第1章 摘要
第2章 癌的概要
第3章 方法論
第4章 目次
第5章 疫苗策略：課題與機會
第6章 癌疫苗的競爭動向
- 國家及企業：由誰領導呢
- 前10大企業佔研究開發的3分之1：不包括大規模企業
- 受認可的癌疫苗：功效
- 癌疫苗的交易與合作
- 近幾年有關癌疫苗的企業收購合併案
- 攝護腺癌的相關交易
- 乳癌的相關交易
- 白血病及淋巴瘤的相關交易
- 癌疫苗送達的相關交易
- 佐藥的相關交易
第7章 腫瘤抗原
第8章 癌疫苗的免疫調節劑與佐藥
第9章 癌疫苗的送達
- 病毒送達
- 介紹
- 使用的病毒
- 複製子RNA及DNA疫苗
- Retrovirus
- Letinvirus
- Adenovirus
- 腺相關病毒
- 單純皰疹病毒
- 痘病毒
- 其他痘病毒
- Baculovirus
- 細菌
- 細胞療法：樹狀細胞及癌細胞療法
- 合成物質送達系統及策略
第10章 不使用抗體的開發中疫苗：各症狀
- 一般腫瘤學概要
- 發展分析：黑色瘤
- 發展分析：乳癌
- 發展分析：攝護腺癌
- 發展分析：肺癌
- 發展分析：結腸直腸癌
- 發展分析：子宮頸部癌
第11章 免責事項
第12章 藥劑索引
第13章 企業索引
Abstract
Introduction
New approaches in vaccines, such as DNA vaccines, new combination vaccines,
new formulations, novel delivery routes, new adjuvants are being explored. In
the last three years the cancer vaccine industry has reshaped itself quite
considerably. The number of cancer vaccine players has rather decreased than
increased, through operational re-prioritizations, M&As and fall outs.
Scope of this report
- In-depth competitive landscape assessment of the cancer vaccine market
- Tumor antigen discovery and technologies surrounding it
- Thorough review of immunomodulating strategies and adjuvants
- Thorough review of cancer vaccine delivery and technologies surrounding it
- Progress analysis of six major cancer vaccine indications, including
players, drugs, clinical progress and pitfalls
Research and analysis highlights
Research and development in the cancer vaccine field is dominated by its top
10 players, interestingly not including any of the big pharma companies per
se. The recent Gardasil approval and GlaxoSmithKline's acquisition of Corixa
will certainly push the industry towards more acquisitions. With this in mind,
this report makes an in-depth assessment of competitive landscape, tumor
antigen technologies, immunostimulatory strategies, vaccine delivery
technologies, and a progress analysis of six major cancer vaccine indications.
Table of Contents
1 Executive Summary
2 Cancer Highlights
3 Methodology
- 4 Table of Contents
- 4.1 List of Boxes
- 4.2 List of Figures
- 4.3 List of Tables
5 Vaccine Strategies: Challenges & Opportunities
6 Competitive Landscape in Cancer Vaccines
- 6.1 Countries & Players: Who are In the Lead?
- 6.1.1 Top 10 Players Constitute Up to One Third of R&D: Big Pharma Not
Included!
- 6.1.2 Approved Cancer Vaccine Drugs: Performance
- 6.2 Deals & Alliances in Cancer Vaccines
- 6.2.1 Recent Mergers & Acquisitions in Cancer Vaccines
- 6.2.2 Deals in Prostate Cancer
- 6.2.3 Deals in Breast Cancer
- 6.2.4 Deals in Leukemia & Lymphoma
- 6.2.5 Drug Delivery Deals in Cancer Vaccines
- 6.2.6 Adjuvant Deals
7 Tumor Antigens
- 7.1 Tumor Antigens: General Comments
- 7.2 Antigen Discovery
- 7.2.1 Classical Immunology Approach
- 7.2.2 The Reverse Immunology Approach
- 7.2.3 Company Platforms
- 7.2.3.1 Epitope Identification System - EIS®
- 7.2.3.2 EPIQUEST system
- 7.2.3.3 MolecularBreeding™ & MaxyScan™
- 7.2.3.4 ProtEx™ technology
- 7.2.3.5 Rapid Identification of Alternative Splicing (RIAS) System
- 7.2.3.6 SMARTOMICS™
- 7.3 Specific Antigen Processing Technologies Increasing Antigen
Presentation
8 Immunomodulators & Adjuvants in Cancer Vaccines
- 8.1 Overview
- 8.2 Cytokines
- 8.2.1 Vaccines in Combination with Interleukin-2
- 8.2.2 Tumor Necrosis Factor
- 8.2.3 Interferons
- 8.3 Adjuvants
- 8.4 Other Immunomodulating Strategies
- 8.4.1 An Immune Response Modifying Protein
- 8.4.2 Immunostimulatory DNA
- 8.4.3 Ex Vivo Stimulated Immune Cells
- 8.4.4 Fusion Protein Gain Potent Immune Response
- 8.4.5 Macrophage and Natural Killer Cells Activation
- 8.4.6 Selective Suppression of the Immune System to An Antigen
- 8.4.7 TAP Technology
9 Cancer Vaccine Delivery
- 9.1 Viral Delivery
- 9.1.1 Introduction
- 9.1.2 Viral Constructs Put into Use
- 9.1.2.1 Replicon-based RNA and DNA vaccines
- 9.1.2.1.1 The Alphavaccine Platform System - ArV™
- 9.1.2.1.2 MVA-BN
- 9.1.2.2 Retroviruses
- 9.1.2.2.1 The SDSV-platform
- 9.1.2.3 Lentivirus
- 9.1.2.3.1 LentiPak™
- 9.1.2.3.2 LentiVector™⁄ pEGASUS™
- 9.1.2.4 Adenoviruses
- 9.1.2.4.1 Failed Adenovirus Delivery Platforms
- 9.1.2.4.2 GVAX
- 9.1.2.4.3 TNFerade™
- 9.1.2.4.4 INGN-225
- 9.1.2.5 Adeno-associated viruses
- 9.1.2.5.1 Failed AAV Delivery Platforms
- 9.1.2.5.2 Genzyme Acquires AAV vector Technology
- 9.1.2.5.3 MediGene's AAV Platform
- 9.1.2.6 Herpes Simplex Viruses
- 9.1.2.6.1 DISC-HSV
- 9.1.2.6.2 ImmunoVEX
- 9.1.2.7 Poxviruses
- 9.1.2.7.1 Hi-8™ PrimeBoost™ platform
- 9.1.2.7.2 PROSTVAC-VF
- 9.1.2.7.3 Transgene's MVA Platform
- 9.1.2.7.4 TroVax
- 9.1.2.8 Other Poxvirus Systems
- 9.1.2.9 Baculovirus
- 9.1.2.9.1 Chimeric virus -like particles (CVLPs)
- 9.2 Bacterias
- 9.3 Cell Therapy: Dendritic-cell Based & Cancer-Cell Based Therapies
- 9.3.1 Introduction
- 9.3.2 Cell Therapy Strategies
- 9.3.2.1 Processed Tumor Cells
- 9.3.2.2 Lysed Tumor Cell Line
- 9.3.2.3 The Dendritic Cell Strategy that Didn't Work Out
- 9.3.2.4 HSPs
- 9.3.2.5 Provenge™
- 9.3.2.6 Dendritophages
- 9.3.2.7 Cell-targeting Antibodies
- 9.3.2.8 Increase Dendritic Cell Number
- 9.3.2.9 DCVax®
- 9.3.2.10 ACTIVATE™
- 9.4 Synthetic Delivery Systems & Strategies
- 9.4.1 Introduction
- 9.4.2 Biotransport™
- 9.4.3 Biotype®vector
- 9.4.4 DNAVax Gene Delivery System
- 9.4.5 FusitAb™
- 9.4.6 GeneDrug™
- 9.4.7 Molecular Conjugates
- 9.4.8 Naked DNA Delivery
- 9.4.9 PVLP Technology
- 9.4.10 Sphingosomal Drug Delivery Technology
- 9.4.11 STEALTH
- 9.4.12 Failed Liposomal Systems
10 Non-Antibody Based Vaccines in Development: By Major Indications
- 10.1 General Oncology Overview
- 10.2 Progress Analysis - Melanoma
- 10.3 Progress Analysis - Breast Cancer
- 10.4 Progress Analysis - Prostate Cancer
- 10.5 Progress Analysis - Lung Cancer
- 10.6 Progress Analysis - Colorectal Cancer
- 10.7 Progress Analysis - Cervical Cancer
11 Disclaimer
- 11.1 Liability
- 11.2 Completeness
12 Drug Index
13 Company Index
|
